IMI2 AIMING TO SIMPLIFY PROCEDURES, ATTRACT MORE PARTICIPANTS
October 2nd, 2013
THE SECOND round of the European Union’s (EU) Innovative Medicines Initiative (IMI2) that starts in the New Year has been designed to ease funding applications by interested companies and other organisations forming consortia to develop innovative drugs, according to Michel Goldman, IMI executive director.“We have to continue to simplify the reporting,” Goldman told Manufacturing Chemist, referring to the financial and narrative reporting requested from grant beneficiaries when they receive European public money.He also wants to continue increasing the ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.